Zeroing in on CRADAs for drug price regulation; 'Right-hand man' on Hillary's team

Zeroing in on CRADAs for drug price regulation

WASHINGTON - Members of Congress have wasted little time signalling their intent to consider regulation of prices for drugs developed with the aid of federal resources.

Pharmaceutical cost containment measures mentioned at last week's hearing on "The Pricing of Drugs Co-Developed by Federal Laboratories and Private Companies" included granting the National Institutes of Health power to regulate prices of drugs developed with federal funds, imposition of price restrictions on orphan drugs, and regulations requiring pharmaceutical companies to grant government greater access to proprietary data in order to determine drug development and marketing costs.

Rep. Ron Wyden, D-Ore., chair of the subcommittee on regulation,

Read the full 1105 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE